CUPR — Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
Company profile
- Sector: Healthcare
- Industry: Medical - Instruments & Supplies
- Country: SG
- Exchange: NASDAQ Global Select
- Employees: 15
- Website: https://www.cuprina.com.sg
Latest SEC filings for CUPR
- 6-K — 2026-10-20
- 6-K — 2026-10-02
- 6-K — 2026-09-29
- 6-K — 2026-09-18
- 6-K — 2026-09-18
- 424B4 — 2026-09-16
- EFFECT — 2026-09-16
- F-1/A — 2026-09-11
- SCHEDULE 13G — 2026-07-28
- F-1 — 2026-07-07
Latest CUPR news
- — Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group (globenewswire.com)
- — Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter’s Over-Allotment Option in Connection with Public Offering (GlobeNewswire Inc.)
- — Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Shares Shorted: Short Interest Up 223.6% in September
Educational tool only — not investment advice.